Skip to main content
Advertisement

< Back to Article

Inefficiencies and Patient Burdens in the Development of the Targeted Cancer Drug Sorafenib: A Systematic Review

Table 1

Properties of extracted trials in our sample.

Note that three trials [43,55,66] tested sorafenib as both monotherapy and in a combination regimen.

Table 1

doi: https://doi.org/10.1371/journal.pbio.2000487.t001